The liver is a silent organ
The liver is a silent organ，
Early screening, early diagnosis and early treatment are crucial
FibroScan® is the world-leading gold standard for non-invasive diagnosis of liver diseases
FibroScan® is the globally recognized gold standard for the evaluation of liver fibrosis and liver steatosis, published in clinical research literature for more than 5,200 articles, obtained more than 200 authoritative guidelines and consensus recommendations for liver diseases
Widely applied in China
Clinical study literature
Authoritative guidelines and society recommendations for liver diseases
Non-invasive solutions for liver disease management
The FibroScan® Q non-invasive liver diagnostic device is a high cost-performance integrated cart system that can be used in multiple departments. Its embedded battery design supports bedside examinations.
Non-invasive solutions for liver disease management
The FibroScan® 630 non-invasive liver diagnostic device features a mobile, all-in-one cart equipped with a 19-inch wide-view HD LCD color touchscreen, integrated control panel, glass-crystal touch-sensitive keyboard, quick-access buttons, and ergonomic streamline armrests. The system includes grayscale B-mode ultrasound image-guided functionality for rapid spleen localization and accurate liver positioning in obese and complex cases.
Non-invasive solutions for liver disease management
The FibroScan® BOX is the smallest and lightest non-invasive liver diagnostic device among the current FibroScan® product line. It is compatible with liver and spleen ultrasound imaging management software and the iConnect SaaS platform, serving as a non-invasive solution for comprehensive liver health management. With flexible acquisition models including outright purchase, rental, and revenue sharing, it provides multi-tier market coverage. This solution is specifically designed for primary healthcare institutions and health management programs, offering a high-value liver disease management strategy for healthcare providers and chronic disease patients.
Non-invasive solutions for liver disease management
The FibroScan® HANDY non-invasive liver diagnostic device is ultra-portable and designed for institutions requiring immediate testing with portable equipment, such as hospitals, community health centers, private clinics, and health check-up centers. It is ideal for liver disease screening and free clinics at primary healthcare facilities. Supplied with a trolley case for easy mobility and deployment, it is well-suited for rapid transfers between various medical settings, meeting both mobile and stationary testing needs.
Non-invasive solutions for liver disease management
It is compatible with the Connect liver and spleen ultrasound imaging management software and the iConnect SaaS platform, serving as a non-invasive solution for full-cycle liver health management.
Non-invasive solutions for liver disease management
The FibroScan® PRO non-invasive liver diagnostic device is a desktop all-in-one system. With integrated grayscale B-mode ultrasound image guidance, it supports simplified liver and spleen localization. It is mainly used in tertiary hospital departments such as hepatology, gastroenterology, and infectious diseases, where there is a high volume of patients and a need to manage complex or advanced cases (e.g., liver cirrhosis, liver transplantation).
Non-invasive solutions for liver disease management
The FibroScan® 530 non-invasive liver diagnostic device features a 15-inch interactive HD LCD touchscreen display. The portable design paired with a trolley case enables convenient mobility and deployment, making it ideal for quick relocation between different healthcare environments and suitable for both mobile and stationary diagnostic scenarios.
FibroScan®Clinical Application
Chronic hepatitis B (HBV)
Chronic hepatitis C (HCV)
Alcoholic liver disease (ALD)
Metabolic dysfunction-associated fatty liver disease (MAFLD)
Autoimmune liver disease
Drug-induced liver injury
Return visit after liver transplantation
Liver cancer
Portal hypertension
HCV-HIV co-infection
Biliary tract disorders
Two core technologies and three pioneering parameters of FibroScan®
Two core technologies of FibroScan®
Three pioneering parameters of FibroScan®
LSM* by VCTE™
Assessment of liver fibrosis basedon liver stiffness
Liver stiffness measurement results
SSM* by VCTE™
Assessment of portal hypertension basedon spleen stiffness
Spleen stiffness measurement results
CAP™
Assessment of liver steatosis basedon controlled attenuation parameters
CAP measurement results
Global Consensus and Guideline Recommendations
200 + clinical guidelines including WHO and authoritative recommendations from academic institutions
